Overview
DNTH market data
Price History
DNTH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.74 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.08 – $107.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.7K · P/B 3.58 · P/S 4,286.96.
Company news
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Benzinga · Jun 12, 2026, 5:25 PM
8-K filing — Dianthus Therapeutics, Inc. /DE/ (DNTH)SEC EDGAR · Jun 12, 2026, 11:00 AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga · Jun 11, 2026, 2:30 PM
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightGlobenewswire Inc · Jun 2, 2026, 5:15 PM